Jo Cavallo

1 week ago | ascopost.com | Jo Cavallo

Applications are now being accepted for the 2025 Integrative Oncology Scholars Program and Integrative Oncology Fellows Program at the University of Michigan in Ann Arbor (https://sites.google.com/view/integrative-oncology-scholars-/home).

2 weeks ago | ascopost.com | Jo Cavallo

Although next-generation sequencing to assist decision-making for genomics-driven therapy in patients with advanced solid tumors has traditionally been conducted using tissue biopsy samples, recent data support the use of plasma-based circulating tumor DNA (ctDNA) for the genomic profiling of solid cancers. However, which method is more accurate and under which clinical circumstances should tissue or liquid biopsy be used are still under investigation.

2 weeks ago | ascopost.com | Jo Cavallo

The U.S. Food and Drug Administration (FDA) approved the first chimeric antigen receptor (CAR) T-cell therapy in 2017 to treat children with acute lymphoblastic leukemia. Over the past decade, other CAR T-cell therapies have been FDA-approved to treat adults with blood cancers, including non-Hodgkin lymphoma and multiple myeloma. However, some blood cancers, including acute myeloid leukemia (AML), present a challenge for cell-based therapies.

2 weeks ago | ascopost.com | Jo Cavallo

Interim results from the VICTORI study showed that an ultrasensitive circulating tumor DNA (ctDNA)-based liquid biopsy assay was effective in detecting signs of cancer recurrence prior to imaging and provided prognostic value within 1 month after surgery in patients with colorectal cancer. The study, conducted by Titmuss et al, was presented during the 2025 American Association for Cancer Research (AACR) Annual Meeting in Chicago (Abstract 3774).

3 weeks ago | ascopost.com | Jo Cavallo

Overall deaths from cancer over the past 2 decades have steadily declined in both men and women in the United States, according to the 2024 Annual Report to the Nation on the Status of Cancer, published today by Sherman et al in Cancer. The report also found that although the incidence of cancer decreased from 2001 to 2013 and then stabilized in men through 2021, among women, overall cancer incidence rates increased slightly every year from 2003 through 2021.